AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts
Move brings together AstraZeneca and Alexion colleagues in a purpose-built facility in Kendall Square, Cambridge, MA, a world leading life sciences hub.AstraZeneca today announced plans to open a new site at the heart of the Cambridge, MA, life sciences and innovation hub. The new site will be a strategic R&D centre for AstraZeneca, as well as Alexion’s new corporate headquarters. The site will bring together approximately 1,500 R&D, commercial and corporate colleagues into a single purpose-built space in Kendall Square, Cambridge, MA. The site, scheduled for completion in 2026, will